Biopharmaceutical CMO And CRO Market Share Analysis Report, 2023-2032
The global biopharmaceutical CMO and CRO market size was exhibited at USD 31.9 billion in 2022 and is projected to hit around USD 61.02 billion by 2032, growing at a CAGR of 6.7% during the forecast period 2023 to 2032.
Key Pointers:
Biopharmaceutical CMO And CRO Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 34.04 Billion |
|
Market Size by 2032 |
USD 61.02 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 6.7% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Source, Service, Product |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Boehringer Ingelheim GmbH; Lonza Group AG; Inno Biologics Sdn Bhd; Rentschler Biopharma SE; JRS Pharma; Biomeva GmbH; ProBioGen AG; Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Toyobo Co., Ltd.; Samsung Biologics; Patheon, CMC Biologics, WuXi Biologics, AbbVie Inc., Binex Co., Ltd., Charles River Laboratories International, Inc., PRA Health Sciences, Parexel International Corporation; Labcorp |
There was unprecedented growth in 2020 due to the COVID-19 pandemic. The rising investments in the biopharmaceutical industry by the prominent participants to enhance their productivity and efficiency have driven the bio manufacturers to increase their focus on outsourcing activities. Currently, biopharma companies have begun outsourcing the resource and capital-intensive steps and, in a few cases, the entire chain of biomanufacturing, thereby boosting the demand for contract-based services.
The coronavirus pandemic has resulted in disruptions in the supply chain of the overall pharmaceutical industry. However, the biopharmaceutical CMO & CRO has responded well to the outbreak as such organizations are the beneficiaries of supply chain disruptions. The CMOs and CROs based in the western hemisphere would especially benefit during the pandemic. For instance, the Australian government partnered with Sandoz and plans to provide an investment of around 50 million euros to spur the production of integrated antibiotics in Europe. Mergers and acquisitions help CMOs offer integrated bioprocessing services to their clients, which, in turn, makes CMOs/CROs an attractive and feasible option for the rapid product launch.
In recent years, the biopharmaceutical industry has witnessed a significant number of consolidations. These consolidations were mainly aimed at business expansion and to stay competitive in the biopharmaceutical contract manufacturing and services market. Although the biopharmaceutical CMO & CRO industry itself is relatively developed, the inception of new bioprocessing tools, novel therapeutics, and the priority shifts in the bio/pharmaceutical industry pertaining to products has increased the pressure on the contract biomanufacturers. As a result, CDMOs are adopting different business models for addressing the needs of their clients and stakeholders in the best possible way.
Furthermore, the integration of single-use systems in production facilities helps the CMOs to economically expand the manufacturing capacity. The single-use products offer fast turnaround and limit allied activities, such as cleaning and changeover validation. However, the contract negotiations between CMOs and customers are observed to be difficult owing to the regulatory landscape and complexity of service. Clients and CMOs are facing issues pertaining to the IP rights, warranty & liabilities, prices & timelines, which increases the complexity of negotiations.
Source Insights
The mammalian segment held the highest market share of more than 56.9% in 2022 owing to the lack of internal expertise in the industry. This is attributed to their capabilities to add human-like post-translational modifications to complex protein therapeutics. Furthermore, the segment is greatly benefited from the introduction of novel and enhanced expression systems, improved process monitoring solutions, cell line engineering tools, automated screening methods, and disposable devices.
These developments have led to more productive and efficient manufacturing of biologics using mammalian cells. Non-mammalian cell lines, such as microbial cell lines, are recognized as potent factories. Innovative strategies are being implemented to identify and explore the potential of various microbes. This, in turn, is anticipated to contribute to the non-mammalian biopharmaceutical manufacturing segment.
Service Insights
The contract research segment is expected to exhibit the fastest CAGR of 7.6% over the forecast period owing to the increasing outsourcing of research activities by biopharmaceutical companies. A substantial number of CMOs and opportunistic CMOs present in the space are engaged in providing biopharma entities with plenty of services including end-to-end coverage from cell cultivation to fill/finish services. Furthermore, clients are investing heavily to outsource the manufacturing aspect of their product development program.
These factors have resulted in the largest share of this segment. On the other hand, CROs are striving to capitalize on the potential avenues in the industry. New market entrants and small-scale players, which are focused on the development of biopharmaceuticals are anticipated to opt for the contract research services for their discovery programs of new candidates, thereby boosting the segment growth.
Product Insights
The biologics segment dominated the market with the largest revenue share of over 82.7% in 2022. This growth is attributed to the high specificity of biologics, complex manufacturing steps, and a higher success rate as compared to other drug molecules. The use of single-use bioreactors, continuous purification processing, disposable plastic containers, and real-time quality analysis has enabled the CMOs to meet the increasing service demand for biologics production effectively.
Furthermore, several companies are investing in biosimilar development to outperform the safety, efficacy, disposition, or cost of earlier in-class innovator drugs. This has increased the level of competition amongst innovator manufacturers, which in turn, is likely to benefit the CMOs.
Regional Insight
North America held the largest revenue share of 34.67% in 2022. This can be attributed to the local presence of several service providers in the region. Also, a significant number of approved products in the U.S. are being manufactured by CMOs. The presence of several small- and mid-size biopharmaceutical entities (SMEs) lack the resources and budget to establish facilities with well-equipped resources. This, in turn, has increased an inter-dependency between CMOs and SMEs in the U.S., resulting in the dominance of the U.S. market. Asia Pacific is expected to grow at a significant CAGR during the forecast period.
The key reason for the rise in outsourcing in Asian countries includes cost-associated benefits, such as lower labor costs and operating costs across the region. India is anticipated to exhibit significant progress owing to the high volume of large molecule production in this country. The lack of global regulatory symmetry for biosimilar approval has significantly driven the Indian market. In 2016, there were 50 approved biosimilars in India, out of which only 24 were approved in Europe and 5 in the U.S.
Some of the prominent players in the Biopharmaceutical CMO And CRO Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Biopharmaceutical CMO And CRO market.
By Source
By Service Type
By Product
By Region
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Nova one advisor’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
Chapter 2 Executive Summary
2.1 Biopharmaceutical CMO & CRO Market Outlook, 2020 - 2032
Chapter 3 Industry Outlook: Market Variables, Trends, & Scope
3.1 Penetration &Growth Prospect Mapping For Contract Manufacturing Service, 2018
3.2 Trend Analysis
3.2.1 Source trend
3.2.2 Service trend
3.2.3 Product trend
3.2.4 Regional trend
3.3 Biopharmaceutical CMO & CRO Market: Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Rising investment by CMOs for capacity expansion
3.3.1.2 Commercial success of biopharmaceuticals and consequent increased demand for the biopharmaceuticals
3.3.1.3 Robust biopharmaceuticals pipeline
3.3.1.4 Cost and time saving benefits offered by contract services
3.3.2 Market restraint analysis
3.3.2.1 Limited outsourcing amongst well-stablished biopharmaceutical manufacturer
3.4 Key Opportunity Analysis
3.4.1 Rising funds in biopharmaceutical indutry
3.4.2 Mergers & acquistion for facility expansion
3.4.2 Growing demand for protein therapeutics
3.5 Industry Analysis - Porter’s
3.5.1 Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes to the low supplier power
3.5.2 Buyer Power: Fragmented nature of biopharmaceutical industry has led to moderate bargaining power of buyers
3.5.3 Substitution Threat: High due to presence of several big pharma companies
3.5.4 New Entrants Threat: Presence of established players coupled with need of adequate capacity results in moderate threat of new entrants
3.5.5 Competitive Rivalry: High due to fragmented nature of market
3.6 Biopharmaceuticals CMO & CRO-SWOT Analysis, By PEST
3.6.1 Political landscape
3.6.2 Economic landscape
3.6.3 Social landscape
3.6.4 Technology landscape
3.7 Biopharmaceuticals CMO & CRO Market: Company Share Analysis
3.8 Competitive Landscape
3.8.1 Strategy Framework
3.8.2 Company Categorization
3.8.3 New Entrants
3.8.4 Mature Players & Leaders
3.9 Trends In Biopharmaceutical Industry
3.10 R&D Landscape Of Biopharmaceuticals
3.11 Customer Relationship Management In Contract Manufacturing
3.11.1 Selection process of CMO
3.11.2 Operations and quality oversight of CMOs
Chapter 4 Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis
4.1 Global Biopharmaceuticals CMO & CRO Market: Source Movement Analysis
4.2 Mammalian Source
4.2.1 Global mammalian source market, 2020 - 2032
4.3 Non-mammalian Source
4.3.1 Global mammalian source market, 2020 - 2032
Chapter 5 Biopharmaceuticals CMO & CRO Market: Service Estimates & Trend Analysis
5.1 Global Biopharmaceuticals CMO & CRO Market: Service Movement Analysis
5.2 Contract Manufacturing, by service
5.2.1 Global contract manufacturing market, 2020 - 2032
5.2.2 Process development
5.2.2.1 Global process development market, 2020 - 2032
5.2.2.2 Downstream processing
5.2.2.2.1 Global downstream processing market, 2020 - 2032
5.2.2.3 Upstream processing
5.2.2.3.1 Global upstream processing market, 2020 - 2032
5.2.3 Fill & finish operations
5.2.3.1 Global fill & finish operations market, 2020 - 2032
5.2.4 Analytical & QC testing
5.2.4.1 Global analytical & QC testing market, 2020 - 2032
5.2.5 Packaging
5.2.5.1 Global contract packaging market, 2020 - 2032
5.3 Contract Research
5.3.1 Global contract research market, 2020 - 2032
5.3.2 Oncology
5.3.2.1 Global oncology market, 2020 - 2032
5.3.3 Inflammation & immunology
5.3.3.1 Global inflammation & immunology market, 2020 - 2032
5.3.4 Cardiology
5.3.4.1 Global cardiology market, 2020 - 2032
5.3.5 Neuroscience
5.3.5.1 Global neuroscience market, 2020 - 2032
5.3.6 Others
5.3.6.1 Global other CRO services market, 2020 - 2032
Chapter 6 Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend Analysis
6.1 Global Biopharmaceuticals CMO & CRO Market: Product Movement Analysis
6.2 Biologics
6.2.1 Global biologics market, 2020 - 2032
6.2.2 Monoclonal Antibodies
6.2.2.1 Global monoclonal antibodies market, 2020 - 2032
6.2.3 Recombinant proteins
6.2.3.1 Global recombinant proteins market, 2020 - 2032
6.2.4 Vaccines
6.2.4.1 Global vaccines market, 2020 - 2032
6.2.5 Antisense, RNAi, & molecular therapy
6.2.5.1 Global antisense, RNAi, &molecular therapy market, 2020 - 2032
6.2.6 Others
6.2.6.1 Global other product market, 2020 - 2032
6.3 Biosimilars
6.3.1 Global biosimilars market, 2020 - 2032
Chapter 7 Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend Analysis, by Service, Source, & Product
7.1 Biopharmaceuticals CMO & CRO Market Share By Region, 2023 & 2032
7.2 North America
7.2.1 North America Biopharmaceuticals CMO & CRO market, 2020 - 2032
7.2.2 U.S.
7.2.2.1 U.S. biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.2.2.2 U.S. biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.2.2.3 U.S. biopharmaceuticals CMO & CRO market, by products, 2020 - 2032
7.2.3 Canada
7.2.3.1 Canada biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.2.3.2 Canada biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.2.3.3 Canada biopharmaceuticals CMO & CRO market, by products, 2020 - 2032
7.3 Europe
7.3.1 Europe Biopharmaceuticals CMO & CRO market, 2018 - 2032
7.3.2 UK
7.3.2.1 UK biopharmaceuticals CMO & CRO market, by source, 2018 - 2032
7.3.2.2 UK biopharmaceuticals CMO & CRO market, by service, 2018 - 2032
7.3.2.3 UK biopharmaceuticals CMO & CRO market, by products, 2018 - 2032
7.3.3 Germany
7.3.3.1 Germany biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.3.3.2 Germany biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.3.3.3 Germany biopharmaceuticals CMO & CRO market, by products, 2020 - 2032
7.3.4 France
7.3.4.1 France biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.3.4.2 France biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.3.4.3 France biopharmaceuticals CMO & CRO market, by products, 2018 - 2032
7.3.5 Italy
7.3.5.1 Italy biopharmaceuticals CMO & CRO market, by source, 2018 - 2032
7.3.5.2 Italy biopharmaceuticals CMO & CRO market, by service, 2018 - 2032
7.3.5.3 Italy biopharmaceuticals CMO & CRO market, by products, 2018 - 2032
7.3.6 Spain
7.3.6.1 Spain biopharmaceuticals CMO & CRO market, by source, 2018 - 2032
7.3.6.2 Spain biopharmaceuticals CMO & CRO market, by service, 2018 - 2032
7.3.6.3 Spain biopharmaceuticals CMO & CRO market, by products, 2018 - 2032
7.4 Asia Pacific
7.4.1 Asia Pacific biopharmaceuticals CMO & CRO market, 2020 - 2032
7.4.2 China
7.4.2.1 China biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.4.2.2 China biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.4.2.3 China biopharmaceuticals CMO & CRO market, by products, 2020 - 2032
7.4.3 India
7.4.3.1 India biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.4.3.2 India biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.4.3.3 India biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.4.4 Japan
7.4.4.1 Japan biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.4.4.2 Japan biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.4.4.3 Japan biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.4.5 Australia
7.4.5.1 Australia biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.4.5.2 Australia biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.4.5.3 Australia biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.4.6 South Korea
7.4.6.1 South Korea biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.4.6.2 South Korea biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.4.6.3 South Korea biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.5 Latin America
7.5.1 Latin America biopharmaceuticals CMO & CRO market, 2020 - 2032
7.5.2 Brazil
7.5.2.1 Brazil biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.5.2.2 Brazil biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.5.2.3 Brazil biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.5.3 Mexico
7.5.3.1 Mexico biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.5.3.2 Mexico biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.5.3.3 Mexico biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.5.4 Colombia
7.5.4.1 Colombia biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.5.4.2 Colombia biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.5.4.3 Colombia biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.5.5 Argentina
7.5.5.1 Argentina biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.5.5.2 Argentina biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.5.5.3 Argentina biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.6 Middle East & Africa (MEA)
7.6.1 Middle East & Africa biopharmaceuticals CMO & CRO market, 2020 - 2032
7.6.2 South Africa
7.6.2.1 South Africa biopharmaceuticals CMO & CRO market, by source, 2020 - 2032
7.6.2.2 South Africa biopharmaceuticals CMO & CRO market, by service, 2020 - 2032
7.6.2.3 South Africa biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.6.3.2 Saudi Arabia biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.6.3.3 Saudi Arabia biopharmaceuticals CMO & CRO market, by products, 2018-2032
7.6.4 UAE
7.6.4.1 UAE biopharmaceuticals CMO & CRO market, by source, 2018-2032
7.6.4.2 UAE biopharmaceuticals CMO & CRO market, by service, 2018-2032
7.6.4.3 UAE biopharmaceuticals CMO & CRO market, by products, 2018-2032
Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Boehringer Ingelheim GmbH
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 LONZA
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Inno Biologics Sdn Bhd
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Rentschler Biotechnologie GmbH
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 JRS PHARMA
8.1.5.1 Company overview
8.1.5.1.1 CELONIC AG
8.1.5.2 Financial performance
8.1.5.2.1 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 BIOMEVA GmbH
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 ProBioGen
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 TOYOBO CO., LTD.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10.4 Strategic initiatives
8.1.11 Patheon
8.1.11.1 Company overview
8.1.11.1.1 DPx
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 CMC Biologics
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Product benchmarking
8.1.12.4 Strategic initiatives
8.1.13 Binex Co., Ltd.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic initiatives
8.1.14 WuXi Biologics
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product benchmarking
8.1.14.4 Strategic initiatives
8.1.15 AbbVie, Inc.
8.1.15.1 Company overview
8.1.15.2 Financial performance
8.1.15.3 Product benchmarking
8.1.15.4 Strategic initiatives
8.1.16 Charles River Laboratories International, Inc
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product benchmarking
8.1.16.4 Strategic initiatives
8.1.17 ICON plc.
8.1.17.1 Company overview
8.1.17.2 Financial performance
8.1.17.3 Product benchmarking
8.1.17.4 Strategic initiatives
8.1.18 LabCorp
8.1.18.1 Company overview
8.1.18.2 Financial performance
8.1.18.3 Product benchmarking
8.1.18.4 Strategic initiatives
8.1.19 Parexel International Corporation
8.1.19.1 Company overview
8.1.19.2 Financial performance
8.1.19.3 Product benchmarking
8.1.19.4 Strategic initiatives
8.1.20 PRA Health Sciences
8.1.20.1 Company overview
8.1.20.2 Financial performance
8.1.20.3 Product benchmarking
8.1.20.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers